Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark Blueshield Neny Addyi Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Addyi (flibanserin) prior authorization and reauthorization form

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a prior authorization and reauthorization request form for Addyi (flibanserin) used to treat hypoactive sexual desire disorder (HSDD) in premenopausal females. It governs requirements providers must submit to Highmark BlueShield for coverage consideration.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyAddyi (flibanserin) prior authorization and reauthorization form
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the Addyi PA form with clinical documentation and provider signature to SPECARE via fax or mail.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    formprior authorization document
    reauthorizationcontains reauthorization section
    HSDD screening

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HSDD & behavioral therapy
    alcohol/substancealcohol/substance screening

    Coverage Criteria & Screening

    Authorization criteria

    Covered when ALL of the following are provided on the form and documented:

    Primary criteria: Patient is a premenopausal female; No current alcohol or substance abuse; Member has a diagnosis of HSDD (hypoactive sexual desire disorder); Provider has documented behavioral therapy consideration/enrollment/failure as applicable; Member has been educated on Addyi administration including the potential adverse effects of alcohol consumption with Addyi.

    These items are captured by yes/no questions on the form.

    The Addyi prior authorization form includes a specific clinical screening item asking whether the member has a current issue with alcohol or substance abuse. A positive response to this item would preclude safe use of flibanserin because of known interaction and safety concerns; therefore the form requires documentation of a yes/no response to this screening question before coverage can be considered.

    Initial Authorization Requirements

    Initial therapy criteria

    Initial authorization documents baseline diagnostic and therapy consideration.

    Initial Authorization: Member is a premenopausal female; Diagnosis of HSDD is present and is not primarily attributable to a co-existing medical or psychiatric condition, substance abuse, or relationship issue (document whether HSDD is related to these factors); Provider has considered behavioral therapy (document whether member is a candidate), documented whether member is currently enrolled in behavioral therapy, and documented whether behavioral therapy has failed if applicable; Member has been educated on Addyi administration and the potential adverse effects of alcohol consumption with Addyi.

    Captured by Clinical Information questions 1–4d on the form.

    Reauthorization / Continuation Requirements

    Reauthorization

    Reauthorization requires documentation of tolerability and benefit.

    Reauthorization: Member is tolerating therapy with Addyi AND member is experiencing improved sexual desire from baseline while on therapy with Addyi.

    Captured as two yes/no questions in the Reauthorization section of the form.

    Provider Actions & Submission Instructions

    Prior Authorization

    Prior Authorization Required

    Prior authorization requires completion of the Addyi PA form including patient, provider, medication, clinical information and signature. A separate, fully completed form must be submitted for each medication with the prescribing physician's signature.

    • Submit a separate completed form for each medication.
    • Fax completed form and all clinical documentation to 1-866-240-8123 or mail to: 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222.
    Documentation Required

    Required Clinical Information

    Complete all required clinical information on the form: medication information (drug name, strength, requested quantity, requested day supply, directions), diagnosis and/or ICD-10 code(s), and answers to the clinical questions below. The prescribing physician (PCP or Specialist) should, in most cases, complete and sign the form.

    • Medication information: Drug name, Drug strength, Requested quantity, Requested day supply (30, 90, Other), Directions.

    Diagnosis & Billing Codes

    Requested diagnosis codesICD-10
    ICD-10Diagnosis and/or ICD-10 code(s) (specific codes to be provided by prescriber)

    Step Therapy / Behavioral Therapy Trial

    RequirementDocumentation on form
    Document whether the member is a candidate for behavioral therapy for HSDD (yes/no)
    Document whether the member is currently enrolled in behavioral therapy for HSDD (yes/no)
    Document whether the member has experienced therapeutic failure of behavioral therapy for HSDD (yes/no)
    If not appropriate, provide reason behavioral therapy is not appropriate (documented on form)

    Clinical Background

    Flibanserin (Addyi) is indicated for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal females. The PA form captures premenopausal status, confirmation of an HSDD diagnosis, and related clinical details including whether the HSDD is attributable to co-existing medical/psychiatric conditions, substance abuse, or relationship issues; it also documents behavioral therapy candidacy, enrollment, or therapeutic failure and whether the member has been educated about alcohol-related adverse effects with Addyi.

    Key Definitions

    HSDD (Hypoactive Sexual Desire Disorder) — form-linked definition
    DefinitionHypoactive sexual desire disorder (HSDD) — diagnosis queried on the form as 'Does the member have a diagnosis of HSDD (hypoactive sexual desire disorder)?' and linked to assessment of related medical/psychiatric conditions, substance abuse, or relationship issues.
    Related condition screeningForm asks whether the HSDD diagnosis is related to a co-existing medical or psychiatric condition, substance abuse, or relationship issue (yes/no).
    Behavioral therapy assessmentForm documents whether the member is a candidate for behavioral therapy, currently enrolled in behavioral therapy, and whether behavioral therapy has failed (yes/no for each).
    Premenopausal status linkForm requires confirmation that the member is a premenopausal female (yes/no), which is part of HSDD eligibility assessment.
    Alcohol/substance screening linkForm asks about current issue with alcohol or substance abuse (yes/no) and whether the member was educated on alcohol-related adverse effects with Addyi, reflecting safety screening tied to HSDD treatment with flibanserin.
    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyAddyi (flibanserin) prior authorization and reauthorization form
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and submit the Addyi PA form with clinical documentation and provider signature to SPECARE via fax or mail.
    SourceLink
    On This Page
    Coverage Criteria & ScreeningInitial Authorization RequirementsReauthorization / Continuation RequirementsProvider Actions & Submission InstructionsDiagnosis & Billing CodesStep Therapy / Behavioral Therapy TrialClinical BackgroundKey Definitions
  1. Diagnosis and/or ICD-10 code(s).
  2. Clinical questionnaire answers (see clinical information callout).
  3. Documentation Required

    Behavioral Therapy Consideration & Clinical Questions

    The form asks whether the member is a premenopausal female; whether there is current alcohol or substance abuse; whether the member has been educated on Addyi administration and the alcohol-related adverse effects; and whether the member has a diagnosis of HSDD. If HSDD is present, the form queries whether the diagnosis is related to medical/psychiatric conditions, substance abuse, or relationship issues, and it asks about behavioral therapy candidacy, current enrollment, and prior therapeutic failure.

    • Is the member a premenopausal female? (Yes/No)
    • Does the member have a current issue with alcohol or substance abuse? (Yes/No)
    • Has the member been educated on Addyi administration including potential adverse effects of alcohol consumption with Addyi? (Yes/No)
    • Does the member have a diagnosis of HSDD (hypoactive sexual desire disorder)? (Yes/No)
    • If HSDD: Is diagnosis related to co-existing medical/psychiatric condition, substance abuse, or relationship issue? (Yes/No)
    • If HSDD: Is the member a candidate for behavioral therapy? (Yes/No)
    • If HSDD: Is the member currently enrolled in behavioral therapy? (Yes/No)
    • If HSDD: Has the member experienced therapeutic failure of behavioral therapy? (Yes/No)
    Denial Risk

    Payment and Authorization Notice

    The submitting provider certifies that the information provided is true, accurate and complete and that the requested services are medically indicated and necessary to the health of the member. Note: Payment is subject to member eligibility. Authorization does not guarantee payment.